Obsace 150mg Tablet ER contains Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of obsessive-compulsive disorder (OCD) and major depressive disorder (MDD). The extended-release formulation allows for once-daily dosing, providing sustained therapeutic plasma concentrations and improved patient compliance. Fluvoxamine acts by inhibiting the reuptake of serotonin in the central nervous system, thereby enhancing serotonergic neurotransmission and alleviating symptoms associated with OCD and depression. Obsace 150mg Tablet ER is typically initiated at a lower dose and titrated based on clinical response and tolerability. Common adverse effects include nausea, headache, insomnia, and somnolence, which are generally transient. Caution is advised in patients with a history of bipolar disorder, seizure disorders, or hepatic impairment. Concomitant use with monoamine oxidase inhibitors, pimozide, or other serotonergic agents may increase the risk of serotonin syndrome and should be avoided. Regular monitoring is recommended during treatment, especially in the initial weeks, to assess efficacy and detect any emergent side effects or suicidal ideation. This medication should be prescribed and used under the supervision of a qualified healthcare professional, with adherence to recommended dosing guidelines to optimize therapeutic outcomes.